How profitable is Silo Pharma Inc. (SILO)?

In FY 2025 (10-K), SILO converted $1.0M of revenue into a 2.8% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Stock Ratings / Health Care / SILO / financials

REVB (36) APVO (35) SBFM (27) HCWB (23) ⌘ Pro Terminal →

Silo Pharma Inc. (SILO) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Q: Where is SILO trading relative to its 50-day, 200-day, and 52-week technical levels?

SILO last traded at $1.21 (-1.63% on volume of 11,587 shares), positioning the stock -28.82% below its 50-day simple moving average ($1.70) and -73.23% below its 200-day simple moving average ($4.52). Across its 52-week range of $1.10 to $10.43, SILO sits at the 1.2% percentile with a 14-day RSI of 34.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.06 to $1.36).

$1.21 -1.63% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.20

Silo Pharma Inc. (SILO) carries a Roarable Rating of E (Strong Sell) with 18/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $2.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SILO Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SILO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Silo Pharma Inc. (NASDAQ: SILO) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 18/100 at a spot price of $1.21 (-1.63% 1D, market cap $2.3M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, SILO ranks #1004 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SILO compare to REVB and APVO in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SILO carries a Roarable E (18/100 RQD), trailing P/E of N/A, gross margin of 38.6%, and ROIC of -35.0%. By comparison, REVB (Revelation Biosciences Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $2.3M) and APVO (Aptevo Therapeutics Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $2.4M). Among the 5-stock peer group, SILO leads on earnings multiple (N/A) while SBFM leads on capital efficiency (-21.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SILO?

▼

Per SILO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001514183), Silo Pharma Inc. generated $72.1K in revenue (0.0% YoY), -$4.2M in net income, and -$4.7M in free cash flow against $7.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.20 (-0.48%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (18/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-12.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-18.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SILO)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (18/100 Composite)

🔍 WHY SILO SCORES 18/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+7/20 pts (39% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 34.9 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+5/20 pts (28% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 3/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$1.22-1.6% Next Q

Q2 (-2Q)

Grade E$1.20+7.5% Next Q

Q3 (-1Q)

Grade E$1.29-6.2% Next Q

Current

Grade E$1.21-12.2% Hist 90D α

Trajectory: E (26) → E (18)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SILO Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SILO currently carries a cautious 18/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.70) and Max Pain ($1.27) forces dealer call-delta covering toward $10.95.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SILO• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SILO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 18%NO 82%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How SILO Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $72.1K

FY24

Rev $72.1K

FY25

Rev $72.1K

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$72.1K	38.6%	-80%	-$4.2M	-$4.7M	-45%
FY 2024	$72.1K	91.9%	-80%	-$4.4M	-$3.8M	-45%
FY 2023	$72.1K	38.6%	-80%	-$3.7M	-$3.2M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SILO)

✓Walkthrough of SILO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SILO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -82.49%▲ RESISTANCE BREAKOUT

2026-11-03O $1.25H $1.25L $1.21C $1.21VOL 12.0K

RES: $1.14SUP: $0.32SMA50: $1.70SMA200: $4.52

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SILO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SILO Butterfly Map → + Track SILO →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. 0.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SILO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SILO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SILO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SILO)

Health Care Rank #1004 of 1015 ⚔️ REVB vs SILO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SILO vs. REVB, APVO, SBFM, HCWB)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Silo Pharma Inc. (SILO) ranks #1004 by composite RQD confidence (18/100, grade E) and #988 by equity capitalization ($2.3M). Within this direct 5-issuer industry benchmark cohort, SILO leads on earnings valuation at N/A trailing P/E, while SBFM leads on capital efficiency and profitability with -21.4% ROIC and 33.8% gross margin. REVB currently holds the highest overall quantitative score in the immediate peer group at 36/100 (D-) compared with SILO at 18/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SILO ACTIVE Silo Pharma Inc.	E	18/100	—	38.6%	-35.0%	-1.63%	$2.3M	Benchmark Subject
REVB Revelation Biosciences Inc.	D-	36/100	—	—	-35.0%	+0.50%	$2.3M	/revb-vs-silo →
APVO Aptevo Therapeutics Inc.	D-	35/100	—	—	-35.0%	+0.75%	$2.4M	/apvo-vs-silo →
SBFM Sunshine Biopharma Inc.	E	27/100	—	33.8%	-21.4%	-6.14%	$2.2M	/sbfm-vs-silo →
HCWB HCW Biologics Inc.	E	23/100	—	20.0%	-35.0%	+1.82%	$2.5M	/hcwb-vs-silo →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001514183 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Silo Pharma Inc. (SILO) reported GAAP revenue of $72.1K (0.0% vs. FY2024 revenue of $72.1K , and 0.0% cumulative change since FY2023) , GAAP net income of -$4.2M, operating cash flow of -$4.7M, and free cash flow of -$4.7M (-21.6% YoY). On the balance sheet, SILO closed FY2025 with $7.6M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$72.1K	-$4.2M	-$4.7M	-$4.7M	$7.6M	—
FY2024 (FY)	2024-12-31	$72.1K	-$4.4M	-$3.8M	-$3.8M	$7.4M	—
FY2023 (FY)	2023-12-31	$72.1K	-$3.7M	-$3.2M	-$3.2M	—	—

3. SILO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SILO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does SILO compare to REVB and APVO in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for SILO?

Where is SILO trading relative to its 50-day, 200-day, and 52-week technical levels?

SILO last traded at $1.21 (-1.63% on volume of 11,587 shares), positioning the stock -28.82% below its 50-day simple moving average ($1.70) and -73.23% below its 200-day simple moving average ($4.52). Across its 52-week range of $1.10 to $10.43, SILO sits at the 1.2% percentile with a 14-day RSI of 34.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.06 to $1.36).

Direct Sub-Reports: SILO RQD Cockpit SILO 12M Forecast SILO Earnings & Move SILO Dividends & DRIP SILO Insiders & 13F SILO Whale Options SILO Profit Sankey SILO News & Why

ROARABLE RATING BRIEF • RQD 18/100 (E) ✓ SEC XBRL & RQD VERIFIED

SILO — Silo Pharma Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Silo Pharma Inc. (SILO) earns a live Roarable RQD composite score of 18/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.21 (-1.63% 1D, market capitalization $2.3M).

Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 38.6%, operating margin of -60.0%, and free cash flow yield of —.
Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (7/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Silo Pharma Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Pharmaceutical Preparations. The profile does not describe specific products, customers, or revenue model.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Silo Pharma Inc. (SILO) reported $72.1K in annual revenue (up from $72.1K in FY2024, 0.0% YoY) and -$4.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($72.1K revenue, -$3.7M net income) through FY2025, SILO scaled operating cash flow to -$4.7M and free cash flow to -$4.7M, backed by $7.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 18/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.10 – $10.43 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— for upstream dependencies, downstream customers, sector correlations, or 2nd-order bottlenecks.

Key Question #1: Can SILO sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $72.1K and free cash flow of -$4.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is SILO's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SILO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Silo Pharma Inc. (SILO) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SILO Debate Forum (3) ↓

🟡 MARKET WIRE TradingView • 22h ago

Silo Pharma, Inc. Estimates – NASDAQ:SILO

TradingView report covering Silo Pharma Inc. (SILO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Silo Pharma, Inc. (SILO) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering Silo Pharma Inc. (SILO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Benzinga • 1d ago

12 Health Care Stocks Moving In Monday's Pre-Market Session - Apimeds Pharmaceuticals (AMEX:APUS), Alecto

Benzinga report covering Silo Pharma Inc. (SILO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Kairos Pharma (NYSEAM:KAPA) - Stock Analysis

Simply Wall St report covering Silo Pharma Inc. (SILO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

Most Active Stocks Today: U.S. Market

TradingKey report covering Silo Pharma Inc. (SILO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingKey • 1d ago

High Dividend Yield Stocks for Income

TradingKey report covering Silo Pharma Inc. (SILO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.siam.in/ • 1d ago

Oppenheimer Holdings (OPY) Slides 3.69% to $103.00 as Shares Pull Back Toward Support - Buyback Factor

https://www.siam.in/ report covering Silo Pharma Inc. (SILO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST https://www.dars.gov.et/ • 1d ago

SHOP Q2 2026 Earnings: EPS Tops Estimates by 2.5% Despite Modest Stock Pullback - Revenue Growth Report

https://www.dars.gov.et/ report covering Silo Pharma Inc. (SILO) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SILO Bull vs. Bear Conversation Board — What's Your Call at $1.21?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SILO 🐻 33% BEARISH CONVICTION

SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $1.54 (+25.2%)

📌 Pinned Debate

Shares trade at $1.25 after falling from a $10.43 52-week high, leaving a low absolute price with cash of $4.7M reported against a $2.4

Don't sleep on SILO's setup in Health Care. Shares trade at $1.25 after falling from a $10.43 52-week high, leaving a low absolute price with cash of $4.7M reported against a $2.4M market cap.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (18/100) backs up the fundamental quality.

CapAlloc_Nerd 🐂 BULL

@SiliconVal_Bull Agree on the RQD 18/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.23 and keeping dry powder in case we test $1.14.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $0.92 (-25.2%)

Spot @ $1.23

Free cash flow of -$4.7M in FY 2025 matches the $4.7M cash balance while the Altman Z-Score of 0.2 and operating margin of -60% signal

I respect the product at Silo Pharma Inc., but the stock at $1.23 is a different story. Free cash flow of -$4.7M in FY 2025 matches the $4.7M cash balance while the Altman Z-Score of 0.2 and operating margin of -60% signal severe forensic and survival risk.. FCF yield is 0.0% and RQD sits at 18/100 (E) — why pay up here when you can wait for next quarter's numbers?